{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T19:19:05Z","timestamp":1767899945065,"version":"3.49.0"},"reference-count":55,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Context.\u2014Matrix metalloproteinase 3 (MMP-3) is expressed in synovial tissues and involved in cartilage destruction in rheumatoid arthritis and osteoarthritis.<\/jats:p>\n                  <jats:p>Objective.\u2014To study whether measurement of MMP-3 serum concentrations is useful to monitor the activity of rheumatoid synovitis.<\/jats:p>\n                  <jats:p>Design.\u2014Levels of MMP-3 in serum and synovial tissue samples obtained from 29 rheumatoid arthritis patients and 20 osteoarthritis patients were measured by the 1-step sandwich enzyme immunoassay system.<\/jats:p>\n                  <jats:p>Results.\u2014Levels of MMP-3 in the serum and synovial samples were significantly higher in rheumatoid arthritis than in osteoarthritis (P &amp;lt; .001), and the levels correlated directly with each other (r = 0.712, P &amp;lt; .001; N = 49). Immunohistochemistry demonstrated almost exclusive localization of MMP-3 to the lining cells in rheumatoid synovium. The immunoreactivity correlated directly with the scores of synovial inflammatory cell infiltration (r = 0.606, P &amp;lt; .001; n = 29) and the MMP-3 levels in the synovial tissues (r = 0.564, P = .001; n = 29) and those in the serum samples (r = 0.529, P = .003; n = 29) in rheumatoid arthritis. Levels of MMP-3 in rheumatoid serum samples dropped to low values at 1 and 2 weeks after total knee arthroplasty, while the levels of C-reactive protein increased at 1 week and the erythrocyte sedimentation rate and counts of white blood cells and platelets were unchanged at 1 and 2 weeks postoperative.<\/jats:p>\n                  <jats:p>Conclusions.\u2014Our results demonstrate that MMP-3 levels in the serum of rheumatoid arthritis patients correlate with the levels produced by the synovial lining cells and suggest that the activity of rheumatoid synovitis can be monitored by measuring serum levels of MMP-3.<\/jats:p>","DOI":"10.5858\/2007-131-563-slomms","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T20:22:14Z","timestamp":1613074934000},"page":"563-570","source":"Crossref","is-referenced-by-count":42,"title":["Serum Levels of Matrix Metalloproteinase 3 (Stromelysin 1) for Monitoring Synovitis in Rheumatoid Arthritis"],"prefix":"10.5858","volume":"131","author":[{"given":"Ari","family":"Kobayashi","sequence":"first","affiliation":[{"name":"From the Department of Pathology, School of Medicine, Keio University, Tokyo, Japan (Drs Kobayashi, Naito, Enomoto, Shiomoi, Kimura, and Okada); the Department of Orthopaedic Surgery, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan (Drs Kobayashi and Inoue); and the Biopharmaceutical Department, Daiichi Fine Chemical Co Ltd, Takaoka, Japan (Dr Obata)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Naito","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, School of Medicine, Keio University, Tokyo, Japan (Drs Kobayashi, Naito, Enomoto, Shiomoi, Kimura, and Okada); the Department of Orthopaedic Surgery, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan (Drs Kobayashi and Inoue); and the Biopharmaceutical Department, Daiichi Fine Chemical Co Ltd, Takaoka, Japan (Dr Obata)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Enomoto","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, School of Medicine, Keio University, Tokyo, Japan (Drs Kobayashi, Naito, Enomoto, Shiomoi, Kimura, and Okada); the Department of Orthopaedic Surgery, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan (Drs Kobayashi and Inoue); and the Biopharmaceutical Department, Daiichi Fine Chemical Co Ltd, Takaoka, Japan (Dr Obata)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Shiomoi","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, School of Medicine, Keio University, Tokyo, Japan (Drs Kobayashi, Naito, Enomoto, Shiomoi, Kimura, and Okada); the Department of Orthopaedic Surgery, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan (Drs Kobayashi and Inoue); and the Biopharmaceutical Department, Daiichi Fine Chemical Co Ltd, Takaoka, Japan (Dr Obata)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tokuhiro","family":"Kimura","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, School of Medicine, Keio University, Tokyo, Japan (Drs Kobayashi, Naito, Enomoto, Shiomoi, Kimura, and Okada); the Department of Orthopaedic Surgery, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan (Drs Kobayashi and Inoue); and the Biopharmaceutical Department, Daiichi Fine Chemical Co Ltd, Takaoka, Japan (Dr Obata)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken'ichi","family":"Obata","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, School of Medicine, Keio University, Tokyo, Japan (Drs Kobayashi, Naito, Enomoto, Shiomoi, Kimura, and Okada); the Department of Orthopaedic Surgery, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan (Drs Kobayashi and Inoue); and the Biopharmaceutical Department, Daiichi Fine Chemical Co Ltd, Takaoka, Japan (Dr Obata)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Inoue","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, School of Medicine, Keio University, Tokyo, Japan (Drs Kobayashi, Naito, Enomoto, Shiomoi, Kimura, and Okada); the Department of Orthopaedic Surgery, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan (Drs Kobayashi and Inoue); and the Biopharmaceutical Department, Daiichi Fine Chemical Co Ltd, Takaoka, Japan (Dr Obata)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunori","family":"Okada","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, School of Medicine, Keio University, Tokyo, Japan (Drs Kobayashi, Naito, Enomoto, Shiomoi, Kimura, and Okada); the Department of Orthopaedic Surgery, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan (Drs Kobayashi and Inoue); and the Biopharmaceutical Department, Daiichi Fine Chemical Co Ltd, Takaoka, Japan (Dr Obata)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3906","reference":[{"key":"2021021021111143400_i1543-2165-131-4-563-b1","article-title":"Role of endogenous proteinases in the degradation of cartilage matrix.","author":"Nagase"},{"key":"2021021021111143400_i1543-2165-131-4-563-b2","article-title":"Proteinases and matrix degradation.","author":"Okada"},{"key":"2021021021111143400_i1543-2165-131-4-563-b3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1146\/annurev.cellbio.17.1.463","article-title":"How matrix metalloproteinases regulate cell behavior.","volume":"17","author":"Sternlicht","year":"2001","journal-title":"Annu Rev Cell Dev Biol"},{"key":"2021021021111143400_i1543-2165-131-4-563-b4","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1161\/01.RES.0000070112.80711.3D","article-title":"Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry.","volume":"92","author":"Visse","year":"2003","journal-title":"Circ Res"},{"key":"2021021021111143400_i1543-2165-131-4-563-b5","doi-asserted-by":"crossref","first-page":"14245","DOI":"10.1016\/S0021-9258(18)67011-5","article-title":"A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components: purification and characterization.","volume":"261","author":"Okada","year":"1986","journal-title":"J Biol Chem"},{"key":"2021021021111143400_i1543-2165-131-4-563-b6","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0014-5793(89)80586-1","article-title":"Degradation of type IX collagen by matrix metalloproteinase 3 (stromelysin) from human rheumatoid synovial cells.","volume":"244","author":"Okada","year":"1989","journal-title":"FEBS Lett"},{"key":"2021021021111143400_i1543-2165-131-4-563-b7","doi-asserted-by":"crossref","first-page":"5625","DOI":"10.1016\/S0021-9258(19)67640-4","article-title":"Sites of stromelysin cleavage in collagen types II, IX, X, and XI of cartilage.","volume":"266","author":"Wu","year":"1991","journal-title":"J Biol Chem"},{"key":"2021021021111143400_i1543-2165-131-4-563-b8","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1042\/bj2950595","article-title":"Matrix metalloproteinases cleave at two distinct sites on human cartilage link protein.","volume":"295","author":"Nguyen","year":"1993","journal-title":"Biochem J"},{"key":"2021021021111143400_i1543-2165-131-4-563-b9","first-page":"151","article-title":"Activation mechanisms of matrix metalloproteinases.","volume":"378","author":"Nagase","year":"1997","journal-title":"Biol Chem"},{"key":"2021021021111143400_i1543-2165-131-4-563-b10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/rheumatology\/37.1.64","article-title":"Comparative immunolocalization studies of collagenase 1 and collagenase 3 production in the rheumatoid lesion, and by human chondrocytes and synoviocytes in vitro.","volume":"37","author":"Tetlow","year":"1998","journal-title":"Br J Rheumatol"},{"key":"2021021021111143400_i1543-2165-131-4-563-b11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.54.1.25","article-title":"Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis.","volume":"54","author":"Hembry","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"2021021021111143400_i1543-2165-131-4-563-b12","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/art.1780400806","article-title":"Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium.","volume":"40","author":"Lindy","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2021021021111143400_i1543-2165-131-4-563-b13","doi-asserted-by":"crossref","first-page":"31504","DOI":"10.1074\/jbc.272.50.31504","article-title":"Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells: regulation by tumor necrosis factor-alpha and doxycycline.","volume":"272","author":"Hanemaaijer","year":"1997","journal-title":"J Biol Chem"},{"key":"2021021021111143400_i1543-2165-131-4-563-b14","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1002\/art.1780390919","article-title":"Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis.","volume":"39","author":"Ahrens","year":"1996","journal-title":"Arthritis Rheum"},{"key":"2021021021111143400_i1543-2165-131-4-563-b15","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1042\/bj2540731","article-title":"The precursor of a metalloendopeptidase from human rheumatoid synovial fibroblasts: purification and mechanisms of activation by endopeptidases and 4-aminophenylmercuric acetate.","volume":"254","author":"Okada","year":"1988","journal-title":"Biochem J"},{"key":"2021021021111143400_i1543-2165-131-4-563-b16","doi-asserted-by":"crossref","first-page":"5783","DOI":"10.1021\/bi00476a020","article-title":"Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate.","volume":"29","author":"Nagase","year":"1990","journal-title":"Biochemistry"},{"key":"2021021021111143400_i1543-2165-131-4-563-b17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0014-5793(89)80657-X","article-title":"Activation of matrix metalloproteinase 3 (stromelysin) and matrix metalloproteinase 2 (\u201cgelatinase\u201d) by human neutrophil elastase and cathepsin G.","volume":"249","author":"Okada","year":"1989","journal-title":"FEBS Lett"},{"key":"2021021021111143400_i1543-2165-131-4-563-b18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1042\/bj3050301","article-title":"Activation of precursors for matrix metalloproteinases 1 (interstitial collagenase) and 3 (stromelysin) by rat mast-cell proteinases I and II.","volume":"305","author":"Suzuki","year":"1995","journal-title":"Biochem J"},{"key":"2021021021111143400_i1543-2165-131-4-563-b19","doi-asserted-by":"crossref","first-page":"21712","DOI":"10.1016\/S0021-9258(19)36670-0","article-title":"Matrix metalloproteinase 9 (92-kDa gelatinase\/type IV collagenase) from HT 1080 human fibrosarcoma cells: purification and activation of the precursor and enzymic properties.","volume":"267","author":"Okada","year":"1992","journal-title":"J Biol Chem"},{"key":"2021021021111143400_i1543-2165-131-4-563-b20","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1074\/jbc.271.3.1544","article-title":"Biochemical characterization of human collagenase-3.","volume":"271","author":"Knauper","year":"1996","journal-title":"J Biol Chem"},{"key":"2021021021111143400_i1543-2165-131-4-563-b21","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/ard.48.8.645","article-title":"Immunolocalization of matrix metalloproteinase 3 (stromelysin) in rheumatoid synovioblasts (B cells): correlation with rheumatoid arthritis.","volume":"48","author":"Okada","year":"1989","journal-title":"Ann Rheum Dis"},{"key":"2021021021111143400_i1543-2165-131-4-563-b22","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/art.1780340903","article-title":"In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium.","volume":"34","author":"Gravallese","year":"1991","journal-title":"Arthritis Rheum"},{"key":"2021021021111143400_i1543-2165-131-4-563-b23","first-page":"1309","article-title":"Stromelysin and tissue inhibitor of metalloproteinases gene expression in rheumatoid arthritis synovium.","volume":"140","author":"Firestein","year":"1992","journal-title":"Am J Pathol"},{"key":"2021021021111143400_i1543-2165-131-4-563-b24","first-page":"680","article-title":"Localization of matrix metalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium.","volume":"66","author":"Okada","year":"1992","journal-title":"Lab Invest"},{"key":"2021021021111143400_i1543-2165-131-4-563-b25","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/ard.59.6.455","article-title":"Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis.","volume":"59","author":"Yoshihara","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"2021021021111143400_i1543-2165-131-4-563-b26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0009-8981(92)90105-Y","article-title":"A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 3 (stromelysin-1) using monoclonal antibodies.","volume":"211","author":"Obata","year":"1992","journal-title":"Clin Chim Acta"},{"key":"2021021021111143400_i1543-2165-131-4-563-b27","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/art.1780380713","article-title":"Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis.","volume":"38","author":"Yoshihara","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2021021021111143400_i1543-2165-131-4-563-b28","first-page":"251","article-title":"Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1\/TIMP-1 complex in rheumatic disease: correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.","volume":"26","author":"Keyszer","year":"1999","journal-title":"J Rheumatol"},{"key":"2021021021111143400_i1543-2165-131-4-563-b29","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/1529-0131(200004)43:4<852::AID-ANR16>3.0.CO;2-7","article-title":"Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis.","volume":"43","author":"Yamanaka","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2021021021111143400_i1543-2165-131-4-563-b30","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s100670200120","article-title":"Changes in the concentration of plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases-1 (TIMP-1) after total joint replacement in patients with arthritis.","volume":"21","author":"Omura","year":"2002","journal-title":"Clin Rheumatol"},{"key":"2021021021111143400_i1543-2165-131-4-563-b31","first-page":"883","article-title":"Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.","volume":"29","author":"Posthumus","year":"2002","journal-title":"J Rheumatol"},{"key":"2021021021111143400_i1543-2165-131-4-563-b32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"2021021021111143400_i1543-2165-131-4-563-b33","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/art.1780290816","article-title":"Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee\u2014 Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association.","volume":"29","author":"Altman","year":"1986","journal-title":"Arthritis Rheum"},{"key":"2021021021111143400_i1543-2165-131-4-563-b34","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1349-7006.1996.tb00266.x","article-title":"Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas.","volume":"87","author":"Iwata","year":"1996","journal-title":"Jpn J Cancer Res"},{"key":"2021021021111143400_i1543-2165-131-4-563-b35","first-page":"467","article-title":"Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas.","volume":"59","author":"Nakamura","year":"1999","journal-title":"Cancer Res"},{"key":"2021021021111143400_i1543-2165-131-4-563-b36","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1023\/A:1006749501682","article-title":"Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human oral squamous cell carcinomas: implications for lymph node metastasis.","volume":"18","author":"Shimada","year":"2000","journal-title":"Clin Exp Metastasis"},{"key":"2021021021111143400_i1543-2165-131-4-563-b37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/(SICI)1097-0215(19960220)69:1<9::AID-IJC3>3.0.CO;2-8","article-title":"Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas.","volume":"69","author":"Nomura","year":"1996","journal-title":"Int J Cancer"},{"key":"2021021021111143400_i1543-2165-131-4-563-b38","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/(SICI)1097-0215(19991022)84:5<470::AID-IJC4>3.0.CO;2-D","article-title":"Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas.","volume":"84","author":"Ueno","year":"1999","journal-title":"Int J Cancer"},{"key":"2021021021111143400_i1543-2165-131-4-563-b39","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/path.1541","article-title":"Activation of pro-MMP-2 mediated by MT1-MMP in human salivary gland carcinomas: possible regulation of pro-MMP-2 activation by TIMP-2.","volume":"202","author":"Kayano","year":"2004","journal-title":"J Pathol"},{"key":"2021021021111143400_i1543-2165-131-4-563-b40","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.2741\/1016","article-title":"The role of matrix metalloproteinases in glioma invasion.","volume":"8","author":"Nakada","year":"2003","journal-title":"Front Biosci"},{"key":"2021021021111143400_i1543-2165-131-4-563-b41","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1023\/A:1023039230052","article-title":"MT1-MMP and MMP-7 in invasion and metastasis of human cancers.","volume":"22","author":"Shiomi","year":"2003","journal-title":"Cancer Metastasis Rev"},{"key":"2021021021111143400_i1543-2165-131-4-563-b42","doi-asserted-by":"crossref","first-page":"6742","DOI":"10.1016\/S0021-9258(18)68705-8","article-title":"The complete primary structure of human matrix metalloproteinase-3: identity with stromelysin.","volume":"263","author":"Saus","year":"1988","journal-title":"J Biol Chem"},{"key":"2021021021111143400_i1543-2165-131-4-563-b43","doi-asserted-by":"crossref","first-page":"17238","DOI":"10.1016\/S0021-9258(17)44894-0","article-title":"Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts: synergistic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression.","volume":"265","author":"MacNaul","year":"1990","journal-title":"J Biol Chem"},{"key":"2021021021111143400_i1543-2165-131-4-563-b44","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/rheumatology\/41.1.78","article-title":"Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis.","volume":"41","author":"Klimiuk","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"2021021021111143400_i1543-2165-131-4-563-b45","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2174\/1566524013363429","article-title":"Regulation of apoptosis and cell cycle activity in rheumatoid arthritis.","volume":"1","author":"Perlman","year":"2001","journal-title":"Curr Mol Med"},{"key":"2021021021111143400_i1543-2165-131-4-563-b46","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/1529-0131(200110)44:10<2263::AID-ART389>3.0.CO;2-1","article-title":"Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis.","volume":"44","author":"Cunnane","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2021021021111143400_i1543-2165-131-4-563-b47","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/BF02249017","article-title":"Detection of stromelysin in synovial fluid and serum from patients with rheumatoid arthritis and osteoarthritis.","volume":"13","author":"Sasaki","year":"1994","journal-title":"Clin Rheumatol"},{"key":"2021021021111143400_i1543-2165-131-4-563-b48","first-page":"1599","article-title":"Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis.","volume":"23","author":"Ishiguro","year":"1996","journal-title":"J Rheumatol"},{"key":"2021021021111143400_i1543-2165-131-4-563-b49","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/147323000102900102","article-title":"C-reactive protein values and erythrocyte sedimentation rates after total hip and total knee arthroplasty.","volume":"29","author":"Bilgen","year":"2001","journal-title":"J Int Med Res"},{"key":"2021021021111143400_i1543-2165-131-4-563-b50","first-page":"409","article-title":"Increased levels of matrix metalloproteinase-3 in sera from patients with active lupus nephritis.","volume":"16","author":"Kotajima","year":"1998","journal-title":"Clin Exp Rheumatol"},{"key":"2021021021111143400_i1543-2165-131-4-563-b51","first-page":"115","article-title":"Changes in serum concentrations of matrix metalloproteinases, tissue inhibitors of metalloproteinases and type IV collagen in patients with various types of glomerulonephritis.","volume":"95","author":"Akiyama","year":"1997","journal-title":"Res Commun Mol Pathol Pharmacol"},{"key":"2021021021111143400_i1543-2165-131-4-563-b52","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/ard.61.2.161","article-title":"Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment.","volume":"61","author":"Ribbens","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"2021021021111143400_i1543-2165-131-4-563-b53","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/ard.62.11.1094","article-title":"Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis.","volume":"62","author":"Tchetverikov","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2021021021111143400_i1543-2165-131-4-563-b54","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/rheumatology\/41.5.484","article-title":"Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis.","volume":"41","author":"Catrina","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"2021021021111143400_i1543-2165-131-4-563-b55","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/ard.61.4.311","article-title":"Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation.","volume":"61","author":"den Broeder","year":"2002","journal-title":"Ann Rheum Dis"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/131\/4\/563\/2762164\/1543-2165(2007)131%255b563_slomms%255d2_0_co_2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/131\/4\/563\/2762164\/1543-2165(2007)131%255b563_slomms%255d2_0_co_2.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:39:42Z","timestamp":1764790782000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/131\/4\/article-p563.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,1]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4,1]]}},"URL":"https:\/\/doi.org\/10.5858\/2007-131-563-slomms","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4,1]]}}}